NEW YORK (GenomeWeb News) - Celera will help Ipsen develop pharmacogenomic tests that could be used in tandem with Ipsen’s hormone-replacement therapies for short stature, the companies said yesterday.
Under the first phase of the multi-year collaboration, Celera will work with the Paris-based specialty pharmaceutical company to locate and characterize genetic markers related to growth failure.
Should those efforts produce successful results, the companies will then develop diagnostic predictors that Ipsen could use in clinical trials. These predictors would then “potentially form the basis for commercial companion diagnostic tests for Ipsen's short stature therapies,” the companies said.
Ipsen will pay Celera an undisclosed sum for the initial phase of the collaboration. Any future payments will depend on the success of the initial phase.